(Unaudited) (Canadian $ in millions, except as noted) |
For the three months ended | |||||||||||
January 31, 2023 |
October 31, 2022 |
January 31, 2022 |
||||||||||
Interest, Dividend and Fee Income |
||||||||||||
Loans |
$ |
$ | |
$ | |
|||||||
Securities (Note 2) |
||||||||||||
Deposits with banks |
||||||||||||
Interest Expense |
||||||||||||
Deposits |
||||||||||||
Subordinated debt |
||||||||||||
Other liabilities |
||||||||||||
Net Interest Income |
||||||||||||
Non-Interest Revenue |
||||||||||||
Securities commissions and fees |
||||||||||||
Deposit and payment service charges |
||||||||||||
Trading revenues (Note 12) |
( |
) |
||||||||||
Lending fees |
||||||||||||
Card fees |
||||||||||||
Investment management and custodial fees |
||||||||||||
Mutual fund revenues |
||||||||||||
Underwriting and advisory fees |
||||||||||||
Securities gains, other than trading (Note 2) |
( |
) | ||||||||||
Foreign exchange gains, other than trading |
||||||||||||
Insurance revenue |
( |
) | ||||||||||
Share of profit (loss) in associates and joint ventures |
||||||||||||
Other |
||||||||||||
Total Revenue |
||||||||||||
Provision for Credit Losses (Note 3) |
( |
) | ||||||||||
Insurance Claims, Commissions and Changes in Policy Benefit Liabilities |
( |
) | ||||||||||
Non-Interest Expense |
||||||||||||
Employee compensation |
||||||||||||
Premises and equipment |
||||||||||||
Amortization of intangible assets |
||||||||||||
Advertising and business development |
||||||||||||
Communications |
||||||||||||
Professional fees |
||||||||||||
Other |
||||||||||||
Income Before Provision for Income Taxes |
||||||||||||
Provision for income taxes (Note 10) |
||||||||||||
Net Income |
$ |
$ | $ | |||||||||
Earnings Per Common Share (Canadian $) (Note 9) |
||||||||||||
Basic |
$ |
$ | $ | |||||||||
Diluted |
||||||||||||
Dividends per common share |
(Unaudited) (Canadian $ in millions) |
For the three months ended | |||||||||||
January 31, 2023 |
October 31, 2022 |
January 31, 2022 |
||||||||||
Net Income |
$ |
$ | $ | |||||||||
Other Comprehensive Income (Loss), net of taxes |
||||||||||||
Items that may subsequently be reclassified to net income |
||||||||||||
Net change in unrealized gains (losses) on fair value through OCI debt securities |
||||||||||||
Unrealized gains (losses) on fair value through OCI debt securities arising during the period (1) |
( |
) | ( |
) | ||||||||
Reclassification to earnings of (gains) losses during the period (2) |
( |
) |
( |
) | ||||||||
( |
) | ( |
) | |||||||||
Net change in unrealized gains (losses) on cash flow hedges |
||||||||||||
Gains (losses) on derivatives designated as cash flow hedges arising during the period (3) |
( |
) | ( |
) | ||||||||
Reclassification to earnings of (gains) losses on derivatives designated as cash flow hedges during the period (4) |
( |
) | ||||||||||
( |
) | ( |
) | |||||||||
Net gains (losses) on translation of net foreign operations |
||||||||||||
Unrealized gains (losses) on translation of net foreign operations |
( |
) |
||||||||||
Unrealized gains (losses) on hedges of net foreign operations (5) |
( |
) | ( |
) | ||||||||
Reclassification to earnings of net losses related to divestitures (6) |
- |
- | ||||||||||
( |
) |
|||||||||||
Items that will not be reclassified to net income |
||||||||||||
Net unrealized gains on fair value through OCI equity securities arising during the period (7) |
- |
- | ||||||||||
Net gains (losses) on remeasurement of pension and other employee future benefit plans (8) |
( |
) |
||||||||||
Net gains (losses) on remeasurement of own credit risk on financial liabilities designated at fair value (9) |
( |
) |
||||||||||
( |
) |
|||||||||||
Other Comprehensive Income (Loss), net of taxes |
( |
) | ||||||||||
Total Comprehensive Income |
$ |
$ | |
$ | |
(1) | Net of income tax (provision) recovery of $ ( |
(2) | Net of income tax provision (recovery) of $ |
(3) | Net of income tax (provision) recovery of $ ( |
(4) | Net of income tax provision (recovery) of $ ( |
(5) | Net of income tax (provision) recovery of $ ( |
(6) | Net of income tax (provision) of na , na, $ |
(7) | Net of income tax (provision) recovery of $ |
(8) | Net of income tax (provision) recovery of $ |
(9) | Net of income tax (provision) recovery of $ o nths ended. |
(Unaudited) (Canadian $ in millions) |
As at | |||||||||||
January 31, 2023 |
October 31, 2022 |
January 31, 2022 |
||||||||||
Assets |
||||||||||||
Cash and Cash Equivalents |
$ |
$ | |
$ | |
|||||||
Interest Bearing Deposits with Banks |
||||||||||||
Securities (Note 2) |
||||||||||||
Trading |
||||||||||||
Fair value through profit or loss |
||||||||||||
Fair value through other comprehensive income |
||||||||||||
Debt securities at amortized cost |
||||||||||||
Investments in associates and joint ventures |
||||||||||||
Securities Borrowed or Purchased Under Resale Agreements |
||||||||||||
Loans (Note 3) |
||||||||||||
Residential mortgages |
||||||||||||
Consumer instalment and other personal |
||||||||||||
Credit cards |
||||||||||||
Business and government |
||||||||||||
Allowance for credit losses (Note 3) |
( |
) |
( |
) | ( |
) | ||||||
Other Assets |
||||||||||||
Derivative instruments |
||||||||||||
Customers’ liability under acceptances |
||||||||||||
Premises and equipment |
||||||||||||
Goodwill |
||||||||||||
Intangible assets |
||||||||||||
Current tax assets |
||||||||||||
Deferred tax assets |
||||||||||||
Other |
||||||||||||
Total Assets |
$ |
$ | $ | |||||||||
Liabilities and Equity |
||||||||||||
Deposits (Note 4) |
$ |
$ | $ | |||||||||
Other Liabilities |
||||||||||||
Derivative instruments |
||||||||||||
Acceptances |
||||||||||||
Securities sold but not yet purchased |
||||||||||||
Securities lent or sold under repurchase agreements |
||||||||||||
Securitization and structured entities’ liabilities |
||||||||||||
Current tax liabilities |
||||||||||||
Deferred tax liabilities |
||||||||||||
Other |
||||||||||||
Subordinated Debt (Note 4) |
||||||||||||
Total Liabilities |
$ |
$ | $ | |||||||||
Equity |
||||||||||||
Preferred shares and other equity instruments (Note 5) |
||||||||||||
Common shares (Note 5) |
||||||||||||
Contributed surplus |
||||||||||||
Retained earnings |
||||||||||||
Accumulated other comprehensive income |
||||||||||||
Total Equity |
||||||||||||
Total Liabilities and Equity |
$ |
$ | $ |
(Unaudited) (Canadian $ in millions) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
Preferred Shares and Other Equity Instruments (Note 5) |
||||||||
Balance at beginning of period |
$ |
$ | |
|||||
Issued during the period |
- | |||||||
Balance at End of Period |
||||||||
Common Shares (Note 5) |
||||||||
Balance at beginning of period |
||||||||
Issued under the Shareholder Dividend Reinvestment and Share Purchase Plan |
- | |||||||
Issued under the Stock Option Plan |
||||||||
Treasury shares sold |
||||||||
Issued to align capital position with increased regulatory requirements as announced by OSFI (Note 5) |
- | |||||||
Issued for the acquisition of Radicle Group Inc. (Notes 5 and 12) |
- | |||||||
Balance at End of Period |
||||||||
Contributed Surplus |
||||||||
Balance at beginning of period |
||||||||
Stock option expense, net of options exercised |
||||||||
Other |
||||||||
Balance at End of Period |
||||||||
Retained Earnings |
||||||||
Balance at beginning of period |
||||||||
Net income |
||||||||
Dividends on preferred shares and distributions payable on other equity instruments |
( |
) |
( |
) | ||||
Dividends on common shares |
( |
) |
( |
) | ||||
Equity issue expense and premium paid on redemption of preferred shares |
( |
) |
- | |||||
Balance at End of Period |
||||||||
Accumulated Other Comprehensive Income (Loss) on Fair Value through OCI Securities, net of taxes |
||||||||
Balance at beginning of period |
( |
) |
||||||
Unrealized gains (losses) on fair value through OCI debt securities arising during the period |
( |
) | ||||||
Unrealized gains on fair value through OCI equity securities arising during the period |
||||||||
Reclassification to earnings of (gains) during the period |
( |
) |
( |
) | ||||
Balance at End of Period |
( |
) |
||||||
Accumulated Other Comprehensive Income (Loss) on Cash Flow Hedges, net of taxes |
||||||||
Balance at beginning of period |
( |
) |
||||||
Gains (losses) on derivatives designated as cash flow hedges arising during the period |
( |
) | ||||||
Reclassification to earnings of losses (gains) on derivatives designated as cash flow hedges during the period |
( |
) | ||||||
Balance at End of Period |
( |
) |
( |
) | ||||
Accumulated Other Comprehensive Income on Translation of Net Foreign Operations, net of taxes |
||||||||
Balance at beginning of period |
||||||||
Unrealized gains (losses) on translation of net foreign operations |
( |
) |
||||||
Unrealized gains (losses) on hedges of net foreign operations |
( |
) | ||||||
Reclassification to earnings of net losses related to divestitures (Note 12) |
||||||||
Balance at End of Period |
||||||||
Accumulated Other Comprehensive Income (Loss) on Pension and Other Employee Future Benefit Plans, net of taxes |
||||||||
Balance at beginning of period |
||||||||
Gains (losses) on remeasurement of pension and other employee future benefit plans |
( |
) |
||||||
Balance at End of Period |
||||||||
Accumulated Other Comprehensive Income (Loss) on Own Credit Risk on Financial Liabilities Designated at Fair Value, net of taxes |
||||||||
Balance at beginning of period |
( |
) | ||||||
Gains (losses) on remeasurement of own credit risk on financial liabilities designated at fair value |
( |
) |
||||||
Balance at End of Period |
( |
) | ||||||
Total Accumulated Other Comprehensive Income |
||||||||
Total Equity |
$ |
$ | |
(Unaudited) (Canadian $ in millions, except as noted) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
Cash Flows from Operating Activities |
||||||||
Net Income |
$ |
$ | |
|||||
Adjustments to determine net cash flows provided by (used in) operating activities: |
||||||||
Securities (gains), other than trading (Note 2) |
( |
) |
( |
) | ||||
Depreciation of premises and equipment |
||||||||
Depreciation of other assets |
||||||||
Amortization of intangible assets |
||||||||
Provision for (recovery of) credit losses (Note 3) |
( |
) | ||||||
Deferred taxes |
( |
) |
||||||
Net loss on divestitures |
||||||||
Changes in operating assets and liabilities: |
||||||||
Net (increase) in trading securities |
( |
) |
( |
) | ||||
Change in derivative instruments – decrease in derivative asset |
||||||||
– (decrease) in derivative liability |
( |
) |
( |
) | ||||
Net (increase) decrease in current tax asset |
( |
) |
||||||
Net (decrease) in current tax liability |
( |
) |
( |
) | ||||
Change in accrued interest – (increase) decrease in interest receivable |
( |
) |
||||||
– increase (decrease) in interest payable |
( |
) | ||||||
Changes in other items and accruals, net |
( |
) | ||||||
Net increase in deposits |
||||||||
Net (increase) in loans |
( |
) |
( |
) | ||||
Net increase in securities sold but not yet purchased |
||||||||
Net increase (decrease) in securities lent or sold under repurchase agreements |
( |
) |
||||||
Net (increase) in securities borrowed or purchased under resale agreements |
( |
) |
( |
) | ||||
Net (decrease) in securitization and structured entities’ liabilities |
( |
) |
( |
) | ||||
Net Cash Provided by (Used in) Operating Activities |
( |
) | ||||||
Cash Flows from Financing Activities |
||||||||
Net increase in liabilities of subsidiaries |
||||||||
Proceeds from issuance of covered bonds |
||||||||
Redemption/buyback of covered bonds |
( |
) |
( |
) | ||||
Proceeds from issuance of subordinated debt (Note 4) |
||||||||
Proceeds from issuance of preferred shares, net of issuance costs (Note 5) |
||||||||
Net proceeds from issuance of common shares (Note 5) |
||||||||
Net proceeds from the sale of treasury shares |
||||||||
Cash dividends and distributions paid |
( |
) |
( |
) | ||||
Repayment of lease liabilities |
( |
) |
( |
) | ||||
Net Cash Provided by Financing Activities |
||||||||
Cash Flows from Investing Activities |
||||||||
Net (increase) decrease in interest bearing deposits with banks |
( |
) | ||||||
Purchases of securities, other than trading |
( |
) |
( |
) | ||||
Maturities of securities, other than trading |
||||||||
Proceeds from sales of securities, other than trading |
||||||||
Premises and equipment – net (purchases) |
( |
) |
( |
) | ||||
Purchased and developed software – net (purchases) |
( |
) |
( |
) | ||||
Acquisition of Radicle Group Inc. (Note 12) |
( |
) |
||||||
Net proceeds from divestitures |
||||||||
Net Cash (Used in) Investing Activities |
( |
) |
( |
) | ||||
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
( |
) |
||||||
Net increase (decrease) in Cash and Cash Equivalents |
( |
) | ||||||
Cash and Cash Equivalents at Beginning of Period |
||||||||
Cash and Cash Equivalents at End of Period |
$ |
$ | |
|||||
Supplemental Disclosure of Cash Flow Information |
||||||||
Net cash provided by operating activities includes: |
||||||||
Interest paid in the period (1) |
$ |
$ | ||||||
Income taxes paid in the period |
$ |
$ | ||||||
Interest received in the period |
$ |
$ | ||||||
Dividends received in the period |
$ |
$ |
(1) | Includes dividends paid on securities sold but not yet purchased. |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||
Carrying value |
Fair value |
Carrying value |
Fair value |
|||||||||||||
Issued or guaranteed by: |
||||||||||||||||
Canadian federal government |
||||||||||||||||
Canadian provincial and municipal governments |
||||||||||||||||
U.S. federal government |
||||||||||||||||
U.S. states, municipalities and agencies |
||||||||||||||||
Other governments |
||||||||||||||||
NHA MBS, U.S. agency MBS and CMO (1) |
||||||||||||||||
Corporate debt |
||||||||||||||||
Total |
(1) | These amounts are either supported by insured mortgages or issued by U.S. agencies and government-sponsored enterprises. NHA refers to the National Housing Act, MBS refers to mortgage-backed securities and CMO refers to collateralized mortgage obligations. |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||||||||||
Cost/ Amortized cost |
Gross unrealized gains |
Gross unrealized losses |
Fair value |
Cost/ Amortized cost |
Gross unrealized gains |
Gross unrealized losses |
Fair value |
|||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||
Canadian federal government |
||||||||||||||||||||||||||||||||
Canadian provincial and municipal governments |
||||||||||||||||||||||||||||||||
U.S. federal government |
||||||||||||||||||||||||||||||||
U.S. states, municipalities and agencies |
||||||||||||||||||||||||||||||||
Other governments |
||||||||||||||||||||||||||||||||
NHA MBS |
||||||||||||||||||||||||||||||||
U.S. agency MBS and CMO |
||||||||||||||||||||||||||||||||
Corporate debt |
||||||||||||||||||||||||||||||||
Corporate equity |
||||||||||||||||||||||||||||||||
Total |
(Canadian $ in millions) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
FVOCI |
||||||||
Amortized cost |
||||||||
Total |
(Canadian $ in millions) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
FVTPL securities |
||||||||
FVOCI securities - realized gains (losses) (1) |
||||||||
Impairment recovery |
||||||||
Securities gains, other than trading |
(1) |
• |
Interest and dividend income of $ |
• |
Gains (losses) from securities designated as FVTPL of $ |
• |
Realized gains from FVOCI securities were $ million for the three months ended January 31, 2023 and 2022. |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||||||||||
Stage 1 |
Stage 2 |
Stage 3 |
Total |
Stage 1 |
Stage 2 |
Stage 3 |
Total |
|||||||||||||||||||||||||
Loans: Residential mortgages |
||||||||||||||||||||||||||||||||
Exceptionally low |
- |
- |
- | - | ||||||||||||||||||||||||||||
Very low |
- |
- | ||||||||||||||||||||||||||||||
Low |
- |
- | ||||||||||||||||||||||||||||||
Medium |
- |
- | ||||||||||||||||||||||||||||||
High |
- |
- | ||||||||||||||||||||||||||||||
Not rated |
- |
- | ||||||||||||||||||||||||||||||
Impaired |
- |
- |
- | - | ||||||||||||||||||||||||||||
Gross residential mortgages |
||||||||||||||||||||||||||||||||
Allowance for credit losses |
||||||||||||||||||||||||||||||||
Carrying amount |
||||||||||||||||||||||||||||||||
Loans: Consumer instalment and other personal |
||||||||||||||||||||||||||||||||
Exceptionally low |
- |
- | ||||||||||||||||||||||||||||||
Very low |
- |
- | ||||||||||||||||||||||||||||||
Low |
- |
- | ||||||||||||||||||||||||||||||
Medium |
- |
- | ||||||||||||||||||||||||||||||
High |
- |
- | ||||||||||||||||||||||||||||||
Not rated |
- |
- | ||||||||||||||||||||||||||||||
Impaired |
- |
- |
- | - | ||||||||||||||||||||||||||||
Gross consumer instalment and other personal |
||||||||||||||||||||||||||||||||
Allowance for credit losses |
||||||||||||||||||||||||||||||||
Carrying amount |
||||||||||||||||||||||||||||||||
Loans: Credit cards (1) |
||||||||||||||||||||||||||||||||
Exceptionally low |
- |
- |
- | - | ||||||||||||||||||||||||||||
Very low |
- |
- |
- | |||||||||||||||||||||||||||||
Low |
- |
- | ||||||||||||||||||||||||||||||
Medium |
- |
- | ||||||||||||||||||||||||||||||
High |
- |
- | ||||||||||||||||||||||||||||||
Not rated |
- |
- | ||||||||||||||||||||||||||||||
Impaired |
- |
- |
- |
- |
- | - | - | - | ||||||||||||||||||||||||
Gross credit cards |
- |
- | ||||||||||||||||||||||||||||||
Allowance for credit losses |
- |
- | ||||||||||||||||||||||||||||||
Carrying amount |
- |
- | ||||||||||||||||||||||||||||||
Loans: Business and government (2) |
||||||||||||||||||||||||||||||||
Acceptable |
||||||||||||||||||||||||||||||||
Investment grade |
- |
- | ||||||||||||||||||||||||||||||
Sub-investment grade |
- |
- | ||||||||||||||||||||||||||||||
Watchlist |
- |
- |
- | - | ||||||||||||||||||||||||||||
Impaired |
- |
- |
- | - | ||||||||||||||||||||||||||||
Gross business and government |
||||||||||||||||||||||||||||||||
Allowance for credit losses |
||||||||||||||||||||||||||||||||
Carrying amount |
||||||||||||||||||||||||||||||||
Gross total loans and acceptances |
||||||||||||||||||||||||||||||||
Net total loans and acceptances |
||||||||||||||||||||||||||||||||
Commitments and financial guarantee contracts |
||||||||||||||||||||||||||||||||
Acceptable |
||||||||||||||||||||||||||||||||
Investment grade |
- |
- | ||||||||||||||||||||||||||||||
Sub-investment grade |
- |
- | ||||||||||||||||||||||||||||||
Watchlist |
- |
- |
- | |||||||||||||||||||||||||||||
Impaired |
- |
- |
- | - | ||||||||||||||||||||||||||||
Allowance for credit losses |
||||||||||||||||||||||||||||||||
Carrying amount (3)(4) |
(1) | Credit card loans are immediately written off when principal or interest payments are |
(2) | Includes customers’ liability under acceptances. |
(3) | Represents the total contractual amounts of undrawn credit facilities and other off-balance sheet exposures, excluding personal lines of credit and credit cards that are unconditionally cancellable at our discretion. |
(4) | Certain commercial borrower commitments are conditional and may include recourse to counterparties. |
(Canadian $ in millions) |
||||||||||||||||||||||||||||||||
For the three months ended |
January 31, 2023 |
January 31, 2022 |
||||||||||||||||||||||||||||||
Stage 1 |
Stage 2 |
Stage 3 |
Total |
Stage 1 |
Stage 2 |
Stage 3 |
Total |
|||||||||||||||||||||||||
Loans: Residential mortgages |
||||||||||||||||||||||||||||||||
Balance as at beginning of period |
||||||||||||||||||||||||||||||||
Transfer to Stage 1 |
( |
) |
- |
- |
( |
) | ( |
) | - | |||||||||||||||||||||||
Transfer to Stage 2 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Transfer to Stage 3 |
- |
( |
) |
- |
- | ( |
) | - | ||||||||||||||||||||||||
Net remeasurement of loss allowance |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Loan originations |
- |
- |
- | - | ||||||||||||||||||||||||||||
Derecognitions and maturities |
( |
) |
( |
) |
- |
( |
) |
( |
) | ( |
) | - | ( |
) | ||||||||||||||||||
Model changes |
( |
) |
- |
( |
) |
- | - | - | - | |||||||||||||||||||||||
Total Provision for Credit Losses (PCL) (1) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Write-offs (2) |
- |
- |
( |
) |
( |
) |
- | - | ( |
) | ( |
) | ||||||||||||||||||||
Recoveries of previous write-offs |
- |
- |
- | - | ||||||||||||||||||||||||||||
Foreign exchange and other |
( |
) |
( |
) |
( |
) |
- | ( |
) | ( |
) | |||||||||||||||||||||
Balance as at end of period |
||||||||||||||||||||||||||||||||
Loans: Consumer instalment and other personal |
||||||||||||||||||||||||||||||||
Balance as at beginning of period |
||||||||||||||||||||||||||||||||
Transfer to Stage 1 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Transfer to Stage 2 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Transfer to Stage 3 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Net remeasurement of loss allowance |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Loan originations |
- |
- |
- | - | ||||||||||||||||||||||||||||
Derecognitions and maturities |
( |
) |
( |
) |
- |
( |
) |
( |
) | ( |
) | - | ( |
) | ||||||||||||||||||
Model changes |
( |
) |
- |
( |
) |
- | - | - | - | |||||||||||||||||||||||
Total PCL (1) |
( |
) | ||||||||||||||||||||||||||||||
Write-offs (2) |
- |
- |
( |
) |
( |
) |
- | - | ( |
) | ( |
) | ||||||||||||||||||||
Recoveries of previous write-offs |
- |
- |
- | - | ||||||||||||||||||||||||||||
Foreign exchange and other |
( |
) |
( |
) |
( |
) |
( |
) |
- | ( |
) | - | ||||||||||||||||||||
Balance as at end of period |
||||||||||||||||||||||||||||||||
Loans: Credit cards |
||||||||||||||||||||||||||||||||
Balance as at beginning of period |
- |
- | ||||||||||||||||||||||||||||||
Transfer to Stage 1 |
( |
) |
- |
- |
( |
) | - | - | ||||||||||||||||||||||||
Transfer to Stage 2 |
( |
) |
- |
- |
( |
) | - | - | ||||||||||||||||||||||||
Transfer to Stage 3 |
( |
) |
( |
) |
- |
- | ( |
) | - | |||||||||||||||||||||||
Net remeasurement of loss allowance |
( |
) |
( |
) | - | |||||||||||||||||||||||||||
Loan originations |
- |
- |
- | - | ||||||||||||||||||||||||||||
Derecognitions and maturities |
( |
) |
( |
) |
- |
( |
) |
( |
) | ( |
) | - | ( |
) | ||||||||||||||||||
Model changes |
- |
- |
- |
- |
( |
) | - | ( |
) | |||||||||||||||||||||||
Total PCL (1) |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Write-offs (2) |
- |
- |
( |
) |
( |
) |
- | - | ( |
) | ( |
) | ||||||||||||||||||||
Recoveries of previous write-offs |
- |
- |
- | - | ||||||||||||||||||||||||||||
Foreign exchange and other |
- |
( |
) |
( |
) |
( |
) |
- | ( |
) | ( |
) | ||||||||||||||||||||
Balance as at end of period |
- |
- | ||||||||||||||||||||||||||||||
Loans: Business and government |
||||||||||||||||||||||||||||||||
Balance as at beginning of period |
||||||||||||||||||||||||||||||||
Transfer to Stage 1 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Transfer to Stage 2 |
( |
) |
( |
) |
- |
( |
) | ( |
) | - | ||||||||||||||||||||||
Transfer to Stage 3 |
( |
) |
( |
) |
- |
- | ( |
) | - | |||||||||||||||||||||||
Net remeasurement of loss allowance |
( |
) |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
Loan originations |
- |
- |
- | - | ||||||||||||||||||||||||||||
Derecognitions and maturities |
( |
) |
( |
) |
- |
( |
) |
( |
) | ( |
) | - | ( |
) | ||||||||||||||||||
Model changes |
- |
- |
- |
- |
( |
) | - | ( |
) | |||||||||||||||||||||||
Total PCL (1) |
( |
) |
( |
) |
( |
) | ( |
) | ||||||||||||||||||||||||
Write-offs (2) |
- |
- |
( |
) |
( |
) |
- | - | ( |
) | ( |
) | ||||||||||||||||||||
Recoveries of previous write-offs |
- |
- |
- | - | ||||||||||||||||||||||||||||
Foreign exchange and other |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Balance as at end of period |
||||||||||||||||||||||||||||||||
Total as at end of period |
||||||||||||||||||||||||||||||||
Comprised of: Loans |
||||||||||||||||||||||||||||||||
Other credit instruments (3) |
(1) | Excludes PCL on other assets of $ ) million recovery for the three months ended January 31, 2022). |
(2) | Generally, we continue to seek recovery on amounts that were written off during the year, unless the loan is sold, we no longer have the right to collect or we have exhausted all reasonable efforts to collect. |
(3) | Other credit instruments, including off-balance sheet items, are recorded in other liabilities in our Consolidated Balance Sheet. |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||||||||||
Gross amount |
Allowance for credit losses on impaired loans (2) |
Allowance for credit losses on performing loans (3) |
Net amount |
Gross amount |
Allowance for credit losses on impaired loans (2) |
Allowance for credit losses on performing loans (3) |
Net amount |
|||||||||||||||||||||||||
By geographic region (1): |
||||||||||||||||||||||||||||||||
Canada |
||||||||||||||||||||||||||||||||
United States |
||||||||||||||||||||||||||||||||
Other countries |
||||||||||||||||||||||||||||||||
Total |
(1) |
Geographic region is based upon the country of ultimate risk. |
(2) | Excludes allowance for credit losses on impaired loans of $ |
(3) | Excludes allowance for credit losses on performing loans of $ |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||
Gross impaired amount (3) |
Allowance for credit losses on impaired loans (4) |
Net impaired amount (3) |
Gross impaired amount (3) |
Allowance for credit losses on impaired loans (4) |
Net impaired amount (3) |
|||||||||||||||||||
Residential mortgages |
||||||||||||||||||||||||
Consumer instalment and other personal |
||||||||||||||||||||||||
Business and government (1) |
||||||||||||||||||||||||
Total |
||||||||||||||||||||||||
By geographic region (2): |
||||||||||||||||||||||||
Canada |
||||||||||||||||||||||||
United States |
||||||||||||||||||||||||
Other countries |
||||||||||||||||||||||||
Total |
(1) | Includes customers’ liability under acceptances. |
(2) | Geographic region is based upon the country of ultimate risk. |
(3) | Gross impaired loans and net impaired loans exclude purchased credit impaired loans. |
(4) | Excludes allowance for credit losses on impaired loans of $ |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||
30 to 89 days |
90 days or more |
Total |
30 to 89 days |
90 days or more |
Total |
|||||||||||||||||||
Residential mortgages |
||||||||||||||||||||||||
Credit card, consumer instalment and other personal |
||||||||||||||||||||||||
Business and government |
||||||||||||||||||||||||
Total |
As at January 31, 2023 |
As at October 31, 2022 |
|||||||||||||||||||||||||||||||||||||||||||||||||
All figures are average annual values |
Benign scenario |
Base scenario |
Adverse scenario |
Benign scenario |
Base scenario |
Adverse scenario |
||||||||||||||||||||||||||||||||||||||||||||
First 12 Months |
Remaining horizon (1) |
First 12 Months |
Remaining horizon (1) |
First 12 Months |
Remaining horizon (1) |
First 12 Months |
Remaining horizon (1) |
First 12 Months |
Remaining horizon (1) |
First 12 Months |
Remaining horizon (1) |
|||||||||||||||||||||||||||||||||||||||
Real GDP growth rates (2) |
||||||||||||||||||||||||||||||||||||||||||||||||||
Canada |
( |
( |
||||||||||||||||||||||||||||||||||||||||||||||||
United States |
( |
( |
||||||||||||||||||||||||||||||||||||||||||||||||
Corporate BBB 10-year spread |
||||||||||||||||||||||||||||||||||||||||||||||||||
Canada |
||||||||||||||||||||||||||||||||||||||||||||||||||
United States |
||||||||||||||||||||||||||||||||||||||||||||||||||
Unemployment rates |
||||||||||||||||||||||||||||||||||||||||||||||||||
Canada |
||||||||||||||||||||||||||||||||||||||||||||||||||
United States |
||||||||||||||||||||||||||||||||||||||||||||||||||
Housing Price Index (2) |
||||||||||||||||||||||||||||||||||||||||||||||||||
Canada (3) |
( |
( |
( |
( |
( |
( |
( |
( |
( |
|||||||||||||||||||||||||||||||||||||||||
United States (4) |
( |
( |
( |
( |
( |
( |
( |
( |
( |
(1) | The remaining forecast period is two years. |
(2) | Real gross domestic product and housing price index are averages of quarterly year-over-year growth rates. |
(3) | In Canada, we use the HPI Benchmark Composite. |
(4) | In the United States, we use the National Case-Shiller House Price Index. |
Payable on demand |
Payable after notice |
Payable on a fixed date (2)(3) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||
(Canadian $ in millions) |
Interest bearing |
Non-interest bearing |
||||||||||||||||||||||
Deposits by: |
||||||||||||||||||||||||
Banks (1) |
||||||||||||||||||||||||
Business and government |
||||||||||||||||||||||||
Individuals |
||||||||||||||||||||||||
Total (4) |
||||||||||||||||||||||||
Booked in: |
||||||||||||||||||||||||
Canada |
||||||||||||||||||||||||
United States |
||||||||||||||||||||||||
Other countries |
||||||||||||||||||||||||
Total |
(1) | Includes regulated and central banks. |
(2) | Includes $ (Bail-In) regime ($Bail-In regime provides certain statutory powers to the Canada Deposit Insurance Corporation, including the ability to convert specified eligible shares and liabilities into common shares if the bank becomes non-viable. |
(3) | Deposits totalling $ million as at October 31, 2022) can be early redeemed, either fully or partially, by customers without penalty. These are classified as payable on a fixed date, based on their remaining contractual maturities. |
(4) | Includes $ million of deposits denominated in U.S. dollars as at January 31, 2023 ($ million as at October 31, 2022), and $ million of deposits denominated in other foreign currencies ($ million as at October 31, 2022). |
(Canadian $ in millions) |
Canada |
United States |
Other |
Total |
||||||||||||
As at January 31, 2023 |
||||||||||||||||
As at October 31, 2022 |
(Canadian $ in millions) |
Less than 3 months |
3 to 6 months |
6 to 12 months |
Over 12 months |
Total |
|||||||||||||||
As at January 31, 2023 |
||||||||||||||||||||
As at October 31, 2022 |
(Canadian $ in millions, except as noted) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||||||||
Number of shares |
Amount |
Dividends declared per share |
Number of shares |
Amount |
Dividends declared per share |
Convertible into |
||||||||||||||||||||||||
Preferred Shares - Classified as Equity |
||||||||||||||||||||||||||||||
Class B – Series 27 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 29 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 31 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 33 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 44 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 46 |
|
|
|
|
|
|
|
(2)(3) | ||||||||||||||||||||||
Class B – Series 50 |
|
- |
|
|
|
|
|
|
(3) | |||||||||||||||||||||
Class B – Series 52 (11) |
|
- |
|
|
- | - | |
|
- |
|
|
(3) | ||||||||||||||||||
Preferred Shares - Classified as Equity |
|
|
|
|
|
|
|
|||||||||||||||||||||||
Other Equity Instruments |
|
|
|
|
|
|
|
|||||||||||||||||||||||
4.800 % |
|
|
|
|
|
|
|
(3)(5) | ||||||||||||||||||||||
4.300 % LRCNs) |
|
|
|
|
|
|
|
(3)(4) (5) | ||||||||||||||||||||||
5.625 % LRCNs) |
|
|
|
|
|
|
|
(3)(4) (5) | ||||||||||||||||||||||
7.325 % LRCNs) |
|
|
|
|
|
|
|
(3)(4) (5) | ||||||||||||||||||||||
Other Equity Instruments |
|
|
|
|
|
|
|
|||||||||||||||||||||||
Preferred Shares and Other Equity Instruments |
|
|
|
|
|
|
|
|||||||||||||||||||||||
Common Shares (6)(7)(8)(9)(10) |
|
|
|
|
|
|
|
(1) | For additional information refer to Notes 16 and 20 of our annual consolidated financial statements for the year ended October 31, 2022. |
(2) | If converted, the holders have the option to convert back to the original preferred shares on subsequent redemption dates, subject to certain conditions. |
(3) | The instruments issued include a non-viability contingent capital provision (NVCC), which is necessary for the preferred shares, AT1 Notes and by virtue of the recourse to Preferred Shares Series 48, Preferred Shares Series 49 and Preferred Shares Series 51 for Series 1, Series 2 and Series 3 LRCNs, respectively, to qualify as regulatory capital under Basel III, (see (4) below). As such, they are convertible into a variable number of our common shares if OSFI announces that the bank is, or is about to become, non-viable or if a federal or provincial government in Canada publicly announces that the bank has accepted or agreed to accept a capital injection, or equivalent support, to avoid non-viability. In such an event, each preferred share, including Preferred Shares Series 48, Preferred Shares Series 49 and Preferred Shares Series 51 for Series 1, Series 2 and Series 3 LRCNs, respectively, and AT1 Notes, is convertible into common shares pursuant to an automatic conversion formula and a conversion price based on the greater of: (i) a floor price of $and (ii) the current market price of our common shares based on the volume weighted average trading price of our common shares on the TSX. The number of common shares issued is determined by dividing the value of the preferred share or other equity instrument, including declared and unpaid dividends, by the conversion price and then applying the multiplier. Non-cumulative dividends on preferred shares are payable quarterly as and when declared by the Board of Directors, except for Class B – Series 50 and 52 preferred share dividends, which are payable semi-annually. |
(4) | Non-deferrable interest is payable semi-annually on the LRCNs at the bank’s discretion. Non-payment of interest will result in a recourse event, with the noteholders’ sole remedy being the holders’ proportionate share of trust assets comprised of our NVCC Preferred Shares Series 48, Preferred Shares Series 49 and Preferred Shares Series 51 for Series 1, Series 2 and Series 3 LRCNs, respectively, which are eliminated on consolidation. In such an event, the delivery of the trust assets will represent the full and complete extinguishment of our obligations under the LRCNs. In circumstances under which NVCC, including the Preferred Shares Series 48, Preferred Shares Series 49 and Preferred Shares Series 51 for Series 1, Series 2 and Series 3 LRCNs, respectively, would be converted into common shares of the bank, the LRCNs would be redeemed and the noteholders’ sole remedy would be their proportionate share of trust assets, then comprised of common shares of the bank received by the trust on conversion. |
(5) | The rates represent the annual interest rate percentage applicable to the notes issued as at the reporting date. |
(6) | The stock options issued under the Stock Option Plan are convertible into |
( 7 ) |
During the three months ended January 31, 2023, we issued |
(8) | Common shares are net of |
(9) | On December 1, 2022, we issued |
(10) |
On December 16, 2022, we issued through public offering and million to align our capital position with increased regulatory requirements as announced by OSFI on December 8, 2022 (refer to Note 7). |
(11) |
On January 31, 2023, we issued Class B - Series 52 Preferred Shares for $ |
(Canadian $ in millions) | January 31, 2023 |
October 31, 2022 | ||||||||||||||
Carrying value |
Fair value |
Carrying value | Fair value | |||||||||||||
Securities (1) |
||||||||||||||||
Amortized cost |
||||||||||||||||
Loans (1)(2) |
||||||||||||||||
Residential mortgages |
||||||||||||||||
Consumer instalment and other personal |
||||||||||||||||
Credit cards |
||||||||||||||||
Business and government |
||||||||||||||||
Deposits (3) |
||||||||||||||||
Securitization and structured entities’ liabilities (4) |
||||||||||||||||
Other liabilities (5) |
||||||||||||||||
Subordinated debt |
(1) | Carrying value is net of allowances for credit losses. |
(2) | Excludes $ |
(3) | Excludes $ |
(4) | Excludes $ |
(5) | Other liabilities include certain other liabilities of subsidiaries, other than deposits. |
(Canadian $ in millions) |
January 31, 2023 |
October 31, 2022 |
||||||||||||||||||||||||||||||
Valued using quoted market prices |
Valued using models (with observable inputs) |
Valued using models (without observable inputs) |
Total |
Valued using quoted market prices |
Valued using models (with observable inputs) |
Valued using models (without observable inputs) |
Total |
|||||||||||||||||||||||||
Trading Securities |
||||||||||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||
Canadian federal government |
- |
- | ||||||||||||||||||||||||||||||
Canadian provincial and municipal governments |
- |
- | ||||||||||||||||||||||||||||||
U.S. federal government |
- |
- | ||||||||||||||||||||||||||||||
U.S. states, municipalities and agencies |
- |
- |
- | |||||||||||||||||||||||||||||
Other governments |
- |
- | ||||||||||||||||||||||||||||||
NHA MBS, and U.S. agency MBS and CMO |
- |
- | ||||||||||||||||||||||||||||||
Corporate debt |
||||||||||||||||||||||||||||||||
Trading loans |
- |
- |
- | - | ||||||||||||||||||||||||||||
Corporate equity |
- |
- |
- | - | ||||||||||||||||||||||||||||
FVTPL Securities |
||||||||||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||
Canadian federal government |
- |
- | ||||||||||||||||||||||||||||||
Canadian provincial and municipal governments |
- |
- | ||||||||||||||||||||||||||||||
U.S. federal government |
- |
- | - | |||||||||||||||||||||||||||||
Other governments |
- |
- |
- | - | ||||||||||||||||||||||||||||
NHA MBS, and U.S. agency MBS and CMO |
- |
- |
- | - | ||||||||||||||||||||||||||||
Corporate debt |
||||||||||||||||||||||||||||||||
Corporate equity |
||||||||||||||||||||||||||||||||
FVOCI Securities |
||||||||||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||
Canadian federal government |
- |
- | ||||||||||||||||||||||||||||||
Canadian provincial and municipal governments |
- |
- | ||||||||||||||||||||||||||||||
U.S. federal government |
- |
- | ||||||||||||||||||||||||||||||
U.S. states, municipalities and agencies |
- |
- | ||||||||||||||||||||||||||||||
Other governments |
- |
- | ||||||||||||||||||||||||||||||
NHA MBS, and U.S. agency MBS and CMO |
- |
- |
- | - | ||||||||||||||||||||||||||||
Corporate debt |
- |
- | ||||||||||||||||||||||||||||||
Corporate equity |
- |
- |
- | - | ||||||||||||||||||||||||||||
Loans |
||||||||||||||||||||||||||||||||
Residential mortgages |
- |
- |
- | - | ||||||||||||||||||||||||||||
Business and government loans |
- |
- | ||||||||||||||||||||||||||||||
- |
- | |||||||||||||||||||||||||||||||
Other Assets (1) |
||||||||||||||||||||||||||||||||
Fair Value Liabilities |
||||||||||||||||||||||||||||||||
Securities sold but not yet purchased |
- |
- | ||||||||||||||||||||||||||||||
Structured note liabilities (2) |
- |
- |
- | - | ||||||||||||||||||||||||||||
Structured deposits (3) |
- |
- |
- | - | ||||||||||||||||||||||||||||
Other liabilities (4) |
||||||||||||||||||||||||||||||||
Derivative Assets |
||||||||||||||||||||||||||||||||
Interest rate contracts |
- |
- | ||||||||||||||||||||||||||||||
Foreign exchange contracts |
- |
|||||||||||||||||||||||||||||||
Commodity contracts |
- | |||||||||||||||||||||||||||||||
Equity contracts |
- | |||||||||||||||||||||||||||||||
Credit default swaps |
- |
- | - | |||||||||||||||||||||||||||||
Derivative Liabilities |
||||||||||||||||||||||||||||||||
Interest rate contracts |
- |
- | ||||||||||||||||||||||||||||||
Foreign exchange contracts |
- | |||||||||||||||||||||||||||||||
Commodity contracts |
- |
- | ||||||||||||||||||||||||||||||
Equity contracts |
- |
- | ||||||||||||||||||||||||||||||
Credit default swaps |
- | |||||||||||||||||||||||||||||||
(1) | Other assets include precious metals, segregated fund assets in our insurance business, certain receivables and other items measured at fair value. |
(2) | These structured note liabilities included in deposits have been designated at FVTPL. |
(3) |
This represents certain embedded options related to structured deposits carried at amortized cost. |
(4) |
Other liabilities include investment contract liabilities and segregated fund liabilities in our insurance business, certain payables and metals deposits that have been designated at FVTPL as well as certain securitization and structured entities’ liabilities measured at FVTPL. |
Range of input values (1) |
||||||||||||||||||
As at January 31, 2023 (Canadian $ in millions, except as noted) |
Reporting line in fair value hierarchy table |
Fair value of assets |
Valuation techniques |
Significant unobservable inputs |
Low |
High |
||||||||||||
Private equity (2) |
Corporate equity | Net asset value | Net asset value | na |
na |
|||||||||||||
EV/EBITDA | Multiple | |||||||||||||||||
NHA MBS, U.S. agency MBS and CMO |
NHA MBS, U.S. agency MBS and CMO | Discounted cash flows | Prepayment rate | |||||||||||||||
Market Comparable | Comparability Adjustment (3) | ( |
(1) | The low and high input values represent the lowest and highest actual level of inputs used to value a group of financial instruments in a particular product category. These input ranges do not reflect the level of input uncertainty, but are affected by the specific underlying instruments within each product category. The input ranges will therefore vary from period to period based on the characteristics of the underlying instruments held at each balance sheet date. |
(2) | Included in private equity is $ |
(3) | Range of input values represents price per security adjustment (Canadian $). |
na |
– not applicable |
(Canadian $ in millions) |
||||||||||||||||
For the three months ended |
January 31, 2023 |
January 31, 2022 |
||||||||||||||
Level 1 to Level 2 |
Level 2 to Level 1 |
Level 1 to Level 2 |
Level 2 to Level 1 |
|||||||||||||
Trading securities |
||||||||||||||||
FVTPL securities |
||||||||||||||||
FVOCI securities |
||||||||||||||||
Securities sold but not yet purchased |
Change in fair value |
Movements |
Transfers |
||||||||||||||||||||||||||||||||||||||
For the three months ended January 31, 2023 (Canadian $ in millions) |
Balance October 31, 2022 |
Included in earnings |
Included in other comprehensive income (1) |
Issuances/ Purchases |
Sales |
Maturities/ Settlement |
Transfers into Level 3 |
Transfers out of Level 3 |
Fair Value as at January 31, 2023 |
Change in unrealized gains (losses) recorded in income for instruments still held (2) |
||||||||||||||||||||||||||||||
Trading Securities |
||||||||||||||||||||||||||||||||||||||||
NHA MBS and U.S. agency MBS and CMO |
( |
) |
( |
) |
( |
) |
- |
( |
) |
( |
) | |||||||||||||||||||||||||||||
Corporate debt |
- |
- |
- |
- |
- |
( |
) |
- |
||||||||||||||||||||||||||||||||
Total trading securities |
( |
) |
( |
) |
( |
) |
- |
( |
) |
( |
) | |||||||||||||||||||||||||||||
FVTPL Securities |
||||||||||||||||||||||||||||||||||||||||
Corporate debt |
- |
- |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||
Corporate equity |
( |
) |
( |
) |
( |
) |
- |
- |
||||||||||||||||||||||||||||||||
Total FVTPL securities |
( |
) |
( |
) |
( |
) |
- |
- |
||||||||||||||||||||||||||||||||
FVOCI Securities |
||||||||||||||||||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||||||||||
U.S. states, municipalities and agencies |
- |
- |
- |
- |
- |
- |
- |
na |
||||||||||||||||||||||||||||||||
Corporate equity |
- |
( |
) |
- |
- |
- |
- |
na |
||||||||||||||||||||||||||||||||
Total FVOCI securities |
- |
( |
) |
- |
- |
- |
- |
na |
||||||||||||||||||||||||||||||||
Business and Government Loans |
- |
- |
- |
( |
) |
- |
- |
- |
||||||||||||||||||||||||||||||||
Other Assets |
( |
) |
- |
- |
( |
) |
- |
- |
( |
) | ||||||||||||||||||||||||||||||
Derivative Assets |
||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts |
( |
) |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Commodity contracts |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
- |
|
Equity contracts |
- | - |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
Total derivative assets |
( |
) |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||
Other Liabilities |
- |
- |
- |
- |
- |
- |
- |
|||||||||||||||||||||||||||||||||
Derivative Liabilities |
||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts |
- | - |
- |
- |
- |
- |
- |
( |
) | |||||||||||||||||||||||||||||||
Credit default swaps |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||||
Total derivative liabilities |
- |
- |
- |
- |
- |
- |
( |
) | ||||||||||||||||||||||||||||||||
Change in fair value |
Movements |
Transfers |
||||||||||||||||||||||||||||||||||||||
For the three months ended January 31, 2022 (Canadian $ in millions) |
Balance October 31, 2021 |
Included in earnings |
Included in other comprehensive income (1) |
Issuances/ Purchases |
Sales |
Maturities/ Settlement |
Transfers into Level 3 |
Transfers out of Level 3 |
Fair Value as at January 31, 2022 |
Change in unrealized gains (losses) recorded in income for instruments still held (2) |
||||||||||||||||||||||||||||||
Trading Securities |
||||||||||||||||||||||||||||||||||||||||
NHA MBS and U.S. agency MBS and CMO |
( |
) | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||||||
Corporate debt |
( |
) | ( |
) | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||||
Total trading securities |
( |
) | ( |
) | - | ( |
) | |||||||||||||||||||||||||||||||||
FVTPL Securities |
||||||||||||||||||||||||||||||||||||||||
Corporate debt |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Corporate equity |
( |
) | - | - | - | |||||||||||||||||||||||||||||||||||
Total FVTPL securities |
( |
) | - | - | - | |||||||||||||||||||||||||||||||||||
FVOCI Securities |
||||||||||||||||||||||||||||||||||||||||
Issued or guaranteed by: |
||||||||||||||||||||||||||||||||||||||||
U.S. states, municipalities and agencies |
- | - | - | - | - | - | - | na |
||||||||||||||||||||||||||||||||
Corporate equity |
- | - | - | - | na |
|||||||||||||||||||||||||||||||||||
Total FVOCI securities |
- | - | - | - | na |
|||||||||||||||||||||||||||||||||||
Business and Government Loans |
- | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
Other Assets |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Derivative Assets |
||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Commodity contracts |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Equity contracts |
- | - |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Total derivative assets |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Other Liabilities |
- | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||
Derivative Liabilities |
||||||||||||||||||||||||||||||||||||||||
Foreign exchange contracts |
- | - |
- |
- |
- |
- |
- |
- |
- |
- |
||||||||||||||||||||||||||||||
Credit default swaps |
- | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||
Total derivative liabilities |
- | - | - | - | - | - | - | - |
(1) | Foreign exchange translation on assets and liabilities held by foreign operations is included in other comprehensive income, net foreign operations. |
(2) | Changes in unrealized gains (losses) on Trading and FVTPL securities still held on January 31, 2023 and 2022 are included in earnings for the period. |
(Canadian $ in millions, except as noted) |
January 31, 2023 |
October 31, 2022 |
||||||
CET1 Capital |
||||||||
Tier 1 Capital |
||||||||
Total Capital |
||||||||
Total Loss-Absorbing Capacity (TLAC) |
||||||||
Risk-Weighted Assets |
||||||||
Leverage Exposures |
||||||||
CET1 Ratio |
||||||||
Tier 1 Capital Ratio |
||||||||
Total Capital Ratio |
||||||||
TLAC Ratio |
||||||||
Leverage Ratio |
||||||||
TLAC Leverage Ratio |
(1) | Calculated in accordance with OSFI’s Capital Adequacy Requirements Guideline, Leverage Requirements Guideline and Total Loss Absorbing Capacity Guideline. |
For stock options granted during the three months ended |
January 31, 2023 |
January 31, 2022 |
||||||
Expected dividend yield |
||||||||
Expected share price volatility |
||||||||
Risk-free rate of return |
% - |
|||||||
Expected period until exercise (in years) |
||||||||
Exercise price ($) |
(Canadian $ in millions) |
||||||||||||||||
Pension benefit plans |
Other employee future benefit plans |
|||||||||||||||
For the three months ended |
January 31, 2023 |
January 31, 2022 |
January 31, 2023 |
January 31, 2022 |
||||||||||||
Current service cost |
||||||||||||||||
Net interest (income) expense on net defined benefit (asset) liability |
( |
) |
( |
) | ||||||||||||
Past service cost (income) |
( |
) |
- | - |
- | |||||||||||
Gain on settlement |
- |
( |
) | - |
- | |||||||||||
Administrative expenses |
- |
- | ||||||||||||||
Remeasurement of other long-term benefits |
- |
- | - |
- | ||||||||||||
Benefits expense |
||||||||||||||||
Government pension plans expense (1) |
- |
- | ||||||||||||||
Defined contribution expense |
- |
- | ||||||||||||||
Total pension and other employee future benefit expenses recognized in the Consolidated Statement of Income |
(1) | Includes Canada Pension Plan, Quebec Pension Plan and U.S. Federal Insurance Contributions Act. |
(Canadian $ in millions, except as noted) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
Net income |
||||||||
Dividends on preferred shares and distributions on other equity instruments |
( |
) |
( |
) | ||||
Net income available to common shareholders |
||||||||
Weighted-average number of common shares outstanding (in thousands) |
||||||||
Basic earnings per common share (Canadian $) |
(Canadian $ in millions, except as noted) |
For the three months ended |
|||||||
January 31, 2023 |
January 31, 2022 |
|||||||
Net income available to common shareholders adjusted for impact of dilutive instruments |
||||||||
Weighted-average number of common shares outstanding (in thousands) |
||||||||
Effect of dilutive instruments |
||||||||
Stock options potentially exercisable (1) |
||||||||
Common shares potentially repurchased |
( |
) |
( |
) | ||||
Weighted-average number of diluted common shares outstanding (in thousands) |
||||||||
Diluted earnings per common share (Canadian $) |
(1) | In computing diluted earnings per share, we excluded average stock options outstanding of with a weighted-average price of $for the three months ended January 31, 2022) as the average share price for the period did not exceed the exercise price. |
(Canadian $ in millions) |
||||||||||||||||||||||||
For the three months ended January 31, 2023 |
Canadian P&C |
U.S. P&C | BMO WM | BMO CM | Corporate Services (1) |
Total | ||||||||||||||||||
Net interest income (2) |
( |
) |
||||||||||||||||||||||
Non-interest revenue |
( |
) |
||||||||||||||||||||||
Total Revenue |
( |
) |
||||||||||||||||||||||
Provision for (recovery of) credit losses on impaired loans |
( |
) |
( |
) |
||||||||||||||||||||
Provision for (recovery of) credit losses on performing loans |
( |
) |
( |
) |
||||||||||||||||||||
Total provision for (recovery of) credit losses |
( |
) |
( |
) |
||||||||||||||||||||
Insurance claims, commissions and changes in policy benefit liabilities |
||||||||||||||||||||||||
Depreciation and amortization |
||||||||||||||||||||||||
Non-interest expense |
||||||||||||||||||||||||
Income (loss) before taxes |
( |
) |
||||||||||||||||||||||
Provision for (recovery of) income taxes |
( |
) |
||||||||||||||||||||||
Reported net income (loss) |
( |
) |
||||||||||||||||||||||
Average assets (3) |
||||||||||||||||||||||||
For the three months ended January 31, 2022 |
Canadian P&C |
U.S. P&C | BMO WM | BMO CM | Corporate Services (1) |
Total | ||||||||||||||||||
Net interest income (2) |
( |
) | ||||||||||||||||||||||
Non-interest revenue |
||||||||||||||||||||||||
Total Revenue |
||||||||||||||||||||||||
Provision for (recovery of) credit losses on impaired loans |
( |
) | ( |
) | ||||||||||||||||||||
Provision for (recovery of) credit losses on performing loans |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
Total provision for (recovery of) credit losses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
Insurance claims, commissions and changes in policy benefit liabilities |
||||||||||||||||||||||||
Depreciation and amortization |
||||||||||||||||||||||||
Non-interest expense |
||||||||||||||||||||||||
Income before taxes |
||||||||||||||||||||||||
Provision fo r income taxes |
||||||||||||||||||||||||
Reported net income |
||||||||||||||||||||||||
Average assets (3) |
(1) | Corporate Services includes Technology and Operations. |
(2) | Operating groups report on a taxable equivalent basis (teb). Revenue and the provision for income taxes are increased on tax-exempt securities to an equivalent before-tax basis to facilitate comparisons of income between taxable and tax-exempt sources. The offset to the groups’ teb adjustments is reflected in Corporate Services revenue and provision for income taxes. |
(3) | Included within average assets are average earning assets, which are comprised of deposits with other banks, deposits at central banks, reverse repos, loans and securities. Total average earning assets for three months ended January 31, 2023 are $ million, including $million for Canadian P&C, $million for U.S. P&C, and $ million for all other operating segments including Corporate Services (for three months ended January 31, 2022 - Total: $ million, Canadian P&C: $ million, U.S. P&C: $ million and all other operating segments: $ million). |
(Canadian $ in millions) |
||||
Radicle |
||||
Goodwill and intangible assets |
||||
Other assets |
||||
Total assets |
||||
Liabilities |
||||
Purchase price |